Antitumor activity and targeting p53-PUMA mRNA expression by 5-flurouracil PLGA-lipid polymeric nanoparticles in mouse mammary carcinomas: comparison to free 5-flurouracil

References

• Abd-Alhaseeb MM, Zaitone SA, Abou-El-Ela SH, Moustafa YM. 2014. Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich’s ascites carcinoma: role of angiotensin (1–7). PLoS One. 9(1):e85891. doi: 10.1371/journal.pone.0085891.
   PubMed Web of Science ®Google Scholar
• Ahamed M, Akhtar MJ, Alhadlaq HA. 2022. Combined effect of single-walled carbon nanotubes and cadmium on human lung cancer cells. Environ Sci Pollut Res Int. 29(58):87844–87857. doi: 10.1007/s11356-022-21933-0.
   PubMed Web of Science ®Google Scholar
• Ahamed M, Akhtar MJ, Khan MAM, Alhadlaq HA. 2021. Co-exposure of Bi2O3 nanoparticles and bezo[a]pyrene-enhanced in vitro cytotoxicity of mouse spermatogonia cells. Environ Sci Pollut Res Int. 28(14):17109–17118. doi: 10.1007/s11356-020-12128-6.
   PubMed Web of Science ®Google Scholar
• Ali BM, Zaitone SA, Shouman SA, Moustafa YM. 2015. Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich’s carcinoma grown in mice: role of thioredoxin-interacting protein. Naunyn Schmiedebergs Arch Pharmacol. 388(12):1271–1282. doi: 10.1007/s00210-015-1163-9.
   PubMed Web of Science ®Google Scholar
• Ali SA, Zaitone SA, Moustafa YM. 2015. Boswellic acids synergize antitumor activity and protect against the cardiotoxicity of doxorubicin in mice bearing Ehrlich’s carcinoma. Can J Physiol Pharmacol. 93(8):695–708. doi: 10.1139/cjpp-2014-0524.
   PubMed Web of Science ®Google Scholar
• Amara S, Alotaibi D, Tiriveedhi V. 2016. NFAT5/STAT3 interaction mediates synergism of high salt with IL-17 towards induction of VEGF-A expression in breast cancer cells. Oncol Lett. 12(2):933–943. doi: 10.3892/ol.2016.4713.
   PubMed Web of Science ®Google Scholar
• Attia M, Enan ET, Hashish AA, M H El-Kannishy S, Gardouh AR, K Tawfik M, Faisal S, El-Mistekawy A, Salama A, Alomar SY, et al. 2021. Chemopreventive effect of 5-flurouracil polymeric hybrid PLGA-lecithin nanoparticles against colon dysplasia model in mice and impact on p53 apoptosis. Biomol. 11(1):109. doi: 10.3390/biom11010109.
   Google Scholar
• Bahr HI, Toraih EA, Mohammed EA, Mohammad HMF, Ali EAI, Zaitone SA. 2015. Chemopreventive effect of leflunomide against Ehrlich’s solid tumor grown in mice: effect on EGF and EGFR expression and tumor proliferation. Life Sci. 141:193–201. doi: 10.1016/j.lfs.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W. 2012. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine (Lond). 7(8):1253–1271. doi: 10.2217/nnm.12.87.
   PubMed Web of Science ®Google Scholar
• Berthet M, Gauthier Y, Lacroix C, Verrier B, Monge C. 2017. Nanoparticle-based dressing: the future of wound treatment? Trends Biotechnol. 35(8):770–784. doi: 10.1016/j.tibtech.2017.05.005.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 66:2–25. doi: 10.1016/j.addr.2013.11.009.
   PubMed Web of Science ®Google Scholar
• Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 2020. 5‐Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 111(9):3142–3154. doi: 10.1111/cas.14532.
   PubMed Web of Science ®Google Scholar
• Bose RJC, Lee SH, Park H. 2016. Lipid-based surface engineering of PLGA nanoparticles for drug and gene delivery applications. Biomater Res. 20(1):34. doi: 10.1186/s40824-016-0081-3.
   PubMedGoogle Scholar
• Céspedes MV, Casanova I, Parreño M, Mangues R. 2006. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol. 8(5):318–329. doi: 10.1007/s12094-006-0177-7.
   PubMedGoogle Scholar
• Chan JM, Zhang L, Yuet KP, Liao G, Rhee J-W, Langer R, Farokhzad OC. 2009. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 30(8):1627–1634. doi: 10.1016/j.biomaterials.2008.12.013.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang X, Lu W, Wu X, Li J. 2016. Molecular imprinting: perspectives and applications. Chem Soc Rev. 45(8):2137–2211. doi: 10.1039/c6cs00061d.
   PubMed Web of Science ®Google Scholar
• Cheng M, He B, Wan T, Zhu W, Han J, Zha B, Chen H, Yang F, Li Q, Wang W, et al. 2012. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One. 7(10):e47115. doi: 10.1371/journal.pone.0047115.
   PubMed Web of Science ®Google Scholar
• Corrie PG. 2008. Cytotoxic chemotherapy: clinical aspects. Medicine (Baltimore). 36(1):24–28. doi: 10.1016/j.mpmed.2007.10.012.
   Google Scholar
• Coskun M, Vermeire S, Nielsen OH. 2017. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 38(2):127–142. doi: 10.1016/j.tips.2016.10.014.
   PubMed Web of Science ®Google Scholar
• Elaidy SM, El-Kherbetawy MK, Abed SY, Alattar A, Alshaman R, Eladl MA, Alamri ES, Al Balawi AN, Zaid A, Elkazzaz AY, et al. 2023. α-Hederin saponin augments the chemopreventive effect of cisplatin against Ehrlich tumors and bioinformatic approach identifying the role of SDF1/CXCR4/p-AKT-1/NFκB signaling. Pharmaceuticals. 16(3):405. doi: 10.3390/ph16030405.
   Web of Science ®Google Scholar
• El-Deiry WS. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 22(47):7486–7495. doi: 10.1038/sj.onc.1206949.
   PubMed Web of Science ®Google Scholar
• Elmeligie S, Khalil NA, Ahmed EM, Emam SH, Zaitone SAB. 2016. Synthesis of new N1-substituted-5-aryl-3-(3,4,5-trimethoxyphenyl)-2-pyrazoline derivatives as antitumor agents targeting the colchicine site on tubulin. Biol Pharm Bull. 39(10):1611–1622. doi: 10.1248/bpb.b16-00277.
   PubMed Web of Science ®Google Scholar
• El-Sherbiny M, El-Sayed RM, Helal MA, Ibrahiem AT, Elmahdi HS, Eladl MA, Bilay SE, Alshahrani AM, Tawfik MK, Hamed ZE, et al. 2021. Nifuroxazide mitigates angiogenesis in Ehlrich’s solid carcinoma: molecular docking, bioinformatic and experimental studies on inhibition of Il-6/Jak2/Stat3 signaling. Molecules. 26(22):6858. doi: 10.3390/molecules26226858.
   PubMed Web of Science ®Google Scholar
• Elsherbiny NM, El-Sherbiny M, Zaitone SA. 2020. Diallyl trisulfide potentiates chemotherapeutic efficacy of doxorubicin in experimentally induced mammary carcinoma: role of Notch signaling. Pathol Res Pract. 216(10):153139. doi: 10.1016/j.prp.2020.153139.
   PubMed Web of Science ®Google Scholar
• Fei P, Bernhard EJ, El-Deiry WS. 2002. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62(24):7316–7327.
   PubMed Web of Science ®Google Scholar
• Fong H, Chun I, Reneker DH. 1999. Beaded nanofibers formed during electrospinning. Polymer (Guildf). 40(16):4585–4592. doi: 10.1016/S0032-3861(99)00068-3.
   Web of Science ®Google Scholar
• Gardouh AR, Barakat BM, Qushawy MKE, El-Kazzaz AY, Sami MM, Zaitone SA. 2018. Antitumor activity of a molecularly imprinted nanopreparation of 5-flurouracil against Ehrlich’s carcinoma solid tumors grown in mice: comparison to free 5-flurouracil. Chem Biol Interact. 295:52–63. doi: 10.1016/j.cbi.2018.04.019.
   PubMedGoogle Scholar
• Ghitman J, Biru EI, Stan R, Iovu H. 2020. Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine. undefined. 193:108805. doi: 10.1016/j.matdes.2020.108805.
   Google Scholar
• Haggag Y, Abdel-Wahab Y, Ojo O, Osman M, El-Gizawy S, El-Tanani M, Faheem A, McCarron P. 2016. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG. Int J Pharm. 499(1–2):236–246. doi: 10.1016/j.ijpharm.2015.12.063.
   PubMed Web of Science ®Google Scholar
• Haggag YA, Matchett KB, Dakir E-H, Buchanan P, Osman MA, Elgizawy SA, El-Tanani M, Faheem AM, McCarron PA. 2017. Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. Int J Pharm. 521(1–2):40–53. doi: 10.1016/j.ijpharm.2017.02.006.
   PubMedGoogle Scholar
• Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. 1998. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 5(3):271–278. doi: 10.1007/BF02303785.
   PubMed Web of Science ®Google Scholar
• Harris SL, Levine AJ. 2005. The p53 pathway: positive and negative feedback loops. Oncogene. 24(17):2899–2908. doi: 10.1038/sj.onc.1208615.
   PubMed Web of Science ®Google Scholar
• Holmer R, Wätzig GH, Tiwari S, Rose-John S, Kalthoff H. 2015. Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells. BMC Cancer. 15(1):975. doi: 10.1186/s12885-015-1950-1.
   PubMedGoogle Scholar
• Hosono K, Yamada E, Endo H, Takahashi H, Inamori M, Hippo Y, Nakagama H, Nakajima A. 2012. Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. World J Gastroenterol. 18(38):5360–5368. doi: 10.3748/wjg.v18.i38.5360.
   PubMed Web of Science ®Google Scholar
• Huang Q, Duan L, Qian X, Fan J, Lv Z, Zhang X, Han J, Wu F, Guo M, Hu G, et al. 2016. IL-17 promotes angiogenic factors IL-6, IL-8, and VEGF production via stat1 in lung adenocarcinoma. Sci Rep. 6(1):36551. doi: 10.1038/srep36551.
   PubMedGoogle Scholar
• Irie T, Tsujii M, Tsuji S, Yoshio T, Ishii S, Shinzaki S, Egawa S, Kakiuchi Y, Nishida T, Yasumaru M, et al. 2007. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer. 121(4):878–883. doi: 10.1002/ijc.22720.
   PubMed Web of Science ®Google Scholar
• Jablonska E, Piotrowski L, Grabowska Z. 1997. Serum levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res. 3(2):126–129. doi: 10.1007/BF02907807.
   PubMedGoogle Scholar
• Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z. 2006. Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 25(29):4056–4066. doi: 10.1038/sj.onc.1209440.
   PubMed Web of Science ®Google Scholar
• Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J. 2006. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology. 70(2):115–125. doi: 10.1159/000093002.
   PubMed Web of Science ®Google Scholar
• Khan MN, Haggag YA, Lane ME, McCarron PA, Tambuwala MM. 2018. Polymeric nano-encapsulation of curcumin enhances its anti-cancer activity in breast (MDA-MB231) and lung (A549) cancer cells through reduction in expression of HIF-1α and nuclear p65 (Rel A). Curr Drug Deliv. 15(2):286–295. doi: 10.2174/1567201814666171019104002.
   PubMed Web of Science ®Google Scholar
• Kuntsche J, Horst JC, Bunjes H. 2011. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J Pharm. 417(1–2):120–137. doi: 10.1016/j.ijpharm.2011.02.001.
   PubMed Web of Science ®Google Scholar
• Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. 2000. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas - PubMed. J Pathol. 192(2):150–158. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G.
   PubMed Web of Science ®Google Scholar
• Li Y, Ogris M, Wagner E, Pelisek J, Rüffer M. 2003. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. Int J Pharm. 259(1–2):93–101. doi: 10.1016/s0378-5173(03)00211-4.
   PubMedGoogle Scholar
• Linnskog R, Jönsson G, Axelsson L, Prasad CP, Andersson T. 2014. Interleukin‐6 drives melanoma cell motility through p38α‐MAPK‐dependent up‐regulation of WNT5A expression. Mol Oncol. 8(8):1365–1378. doi: 10.1016/j.molonc.2014.05.008.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25(4):402–408. doi: 10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. 2004. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell. 6(3):297–305. doi: 10.1016/j.ccr.2004.08.012.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature. 454(7203):436–444. doi: 10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• Muddineti OS, Ghosh B, Biswas S. 2015. Current trends in using polymer coated gold nanoparticles for cancer therapy. Int J Pharm. 484(1-2):252–267. doi: 10.1016/j.ijpharm.2015.02.038.
   PubMedGoogle Scholar
• Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. 2019. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine. 14:1937–1952. doi: 10.2147/IJN.S198353.
   PubMed Web of Science ®Google Scholar
• Nilsson MB, Langley RR, Fidler IJ. 2005. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 65(23):10794–10800. doi: 10.1158/0008-5472.CAN-05-0623.
   PubMed Web of Science ®Google Scholar
• Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. 2006. Angiogenesis in cancer. Vasc Health Risk Manag. 2(3):213–219. doi: 10.2147/vhrm.2006.2.3.213.
   PubMedGoogle Scholar
• Ozaslan M, Didem Karagoz I, Kilic IH, Guldur ME. 2013. Ehrlich ascites carcinoma. African J Biotechnol. 10(13):2375–2378.
   Google Scholar
• Pandurangan AK, Esa NM. 2014. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review. Asian Pac J Cancer Prev. 15(14):5501–5508. doi: 10.7314/apjcp.2014.15.14.5501.
   PubMedGoogle Scholar
• Rao S, Prestidge CA. 2016. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv. 13(5):691–707. doi: 10.1517/17425247.2016.1151872.
   PubMed Web of Science ®Google Scholar
• Rezvantalab S, Drude NI, Moraveji MK, Güvener N, Koons EK, Shi Y, Lammers T, Kiessling F. 2018. PLGA-Based Nanoparticles in Cancer Treatment. Front Pharmacol. 9:1260. doi: 10.3389/fphar.2018.01260.
   PubMed Web of Science ®Google Scholar
• Russo A, Saide A, Smaldone S, Faraonio R, Russo G. 2017. Role of uL3 in multidrug resistance in p53-mutated lung cancer cells. Int J Mol Sci. 18(3):547. doi: 10.3390/ijms18030547.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J. 2003. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol. 84(3):151–159. doi: 10.1002/jso.10305.
   PubMed Web of Science ®Google Scholar
• Sakhrani NM, Padh H. 2013. Organelle targeting: third level of drug targeting. Drug Des Devel Ther. 7:585–599. doi: 10.2147/DDDT.S45614.
   PubMed Web of Science ®Google Scholar
• Shehatta NH, Okda TM, Omran GA, Abd-Alhaseeb MM. 2022. Baicalin; a promising chemopreventive agent, enhances the antitumor effect of 5-FU against breast cancer and inhibits tumor growth and angiogenesis in Ehrlich solid tumor. Biomed Pharmacother. 146:112599. doi: 10.1016/j.biopha.2021.112599.
   PubMed Web of Science ®Google Scholar
• Suliman FA, Khodeer DM, Ibrahiem A, Mehanna ET, El-Kherbetawy MK, Mohammad HMF, Zaitone SA, Moustafa YM. 2018. Renoprotective effect of the isoflavonoid biochanin A against cisplatin induced acute kidney injury in mice: effect on inflammatory burden and p53 apoptosis. Int Immunopharmacol. 61:8–19. doi: 10.1016/j.intimp.2018.05.010.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Matsubara H. 2011. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011:978312–978317. doi: 10.1155/2011/978312.
   PubMedGoogle Scholar
• Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature. 408(6810):307–310. doi: 10.1038/35042675.
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. 2004. TNF and cancer: good or bad? Cancer Ther. 2:131–148.
   Google Scholar
• Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. 2014. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 11(5):282–298. doi: 10.1038/nrclinonc.2014.51.
   PubMed Web of Science ®Google Scholar
• Wu B, Lu ST, Zhang LJ, Zhuo RX, Xu HB, Huang SW. 2017. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment. Int J Nanomedicine. 12:1853–1862. doi: 10.2147/IJN.S131235.
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature. 407(6801):242–248. doi: 10.1038/35025215.
   PubMed Web of Science ®Google Scholar
• Zhang M, Gong W, Zhang Y, Yang Y, Zhou D, Weng M, Qin Y, Jiang A, Ma F, Quan Z, et al. 2015. Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer. Mol Med Rep. 11(5):3539–3546. doi: 10.3892/mmr.2014.3143.
   PubMed Web of Science ®Google Scholar